Literature DB >> 20425880

Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.

Jason Grebely1, Elizabeth Knight, Krista A Genoway, Mark Viljoen, Milan Khara, Doug Elliott, Lesley Gallagher, Michelle Storms, Jesse D Raffa, Stanley DeVlaming, Fiona Duncan, Brian Conway.   

Abstract

OBJECTIVES: We evaluated assessment and treatment for hepatitis C virus (HCV) among illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary community health centre.
METHODS: From March 2005 to 2008, HCV-infected individuals were referred to a weekly peer-support group and assessed for HCV infection. A retrospective chart review of outcomes 3 years after the initiation of the group was conducted (including HCV assessment and treatment).
RESULTS: Two hundred and four HCV antibody-positive illicit drug users accepted referral to a weekly HCV peer-support group. Assessment for HCV occurred in 53% of patients(n= 109), with 13% (n= 14) having initiated or completed treatment for HCV infection before attending the support group, evaluation ongoing in 10% (n= 11) and treatment deferred/not indicated in 25% (n= 27). The major reasons for HCV treatment deferral included early disease (30%),drug dependence (37%), other medical (11%) or psychiatric comorbidities (4%). Sixty-eight percent of those deferred for reasons other than early liver disease showed multiple reasons for treatment deferral. The first 4 weeks of support group attendance predicted successful HCV assessment (odds ratio: 6.03, 95% confidence interval:3.27-11.12, P < 0.001). Overall, 28% (n= 57) received treatment. Among individuals having completed pegylated-interferon and ribavirin therapy with appropriate follow-up (n =19), the rate of sustained virologic response was 63% (12/19), despite illicit drug use in 53%.
CONCLUSION: A high proportion of illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary health centre were assessed and treated for HCV infection. Peer support coupled with multidisciplinary care is an effective strategy for engaging illicit drug users in HCV care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425880     DOI: 10.1097/meg.0b013e32832a8c4c

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  43 in total

1.  Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

Authors:  Megan G Hofmeister; Jennifer R Havens; April M Young
Journal:  J Prim Prev       Date:  2017-10

2.  Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.

Authors:  Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta
Journal:  J Subst Abuse Treat       Date:  2019-01-30

Review 3.  Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?

Authors:  Donna M Evon; Carol E Golin; Michael W Fried; Francis J Keefe
Journal:  J Consult Clin Psychol       Date:  2012-06-25

4.  Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Authors:  Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash
Journal:  J Clin Virol       Date:  2020-01-27       Impact factor: 3.168

5.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

Review 6.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

7.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

8.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

Review 9.  Using Digital Interventions to Support Individuals with Alcohol Use Disorder and Advanced Liver Disease: A Bridge Over Troubled Waters.

Authors:  Brian Suffoletto; Steve Scaglione
Journal:  Alcohol Clin Exp Res       Date:  2018-06-13       Impact factor: 3.455

10.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.